Investment
Features
FeesSafety
Academy
More
Pluang+

Bitcoin faces selling pressure but long-term holders and potential 401(k) access could boost demand soon.

Market News
18 Aug 2026
Bitcoin
View Source
Bearish
pluang ai news

Bitcoin is currently under selling pressure from ETF outflows, corporate sales, and mining challenges, trading near $64,700, about half its peak in late 2025. Despite these headwinds, longer-term bullish factors include a record increase in long-term holder supply, potential regulatory clarity from the upcoming CLARITY Act vote, and the possibility of 401(k) retirement plans gaining easier access to bitcoin investments. These factors could attract fresh capital and reduce available supply, potentially driving prices higher in the fourth quarter if demand returns. However, much depends on Federal Reserve rate decisions and whether institutional buyers re-enter the market.

More News

Grocery Outlet posts Q2 revenue growth and beats EPS forecasts amid strategic restructuring.

Grocery Outlet posts Q2 revenue growth and beats EPS forecasts amid strategic restructuring.

Grocery Outlet Holding Corp. reported a 1.1% revenue increase to $1.19 billion in Q2 2026 and an adjusted EPS of $0.20, beating analyst expectations despite a 13% EPS decline. The company is undergoing strategic restructuring, including closing 36 un...

Company Fundamentals
Bullish
2 hours ago
Hesai posts revenue beat and 60% net income growth despite EPS miss in Q2 2026

Hesai posts revenue beat and 60% net income growth despite EPS miss in Q2 2026

Hesai Group reported Q2 2026 earnings with revenue of $126.9 million, slightly above expectations, driven by strong LiDAR sales. Despite an EPS of $0.01 missing the $0.08 estimate, the company achieved its fifth consecutive GAAP profitable quarter, w...

Company Fundamentals
Bullish
2 hours ago
Amylyx Pharma shares jump 54% on positive Phase 3 trial for avexitide reducing hypoglycemia.

Amylyx Pharma shares jump 54% on positive Phase 3 trial for avexitide reducing hypoglycemia.

Amylyx Pharmaceuticals' stock surged 54.43% after its drug avexitide showed positive Phase 3 trial results, cutting hypoglycemic events by 55% in post-bariatric patients. UBS set a $45 price target, implying a 36% upside from current levels. The stoc...

Market News
Bullish
4 hours ago
Ondas boosts growth with Aran Defense acquisition and strong Q2 revenue, raising 2026 outlook.

Ondas boosts growth with Aran Defense acquisition and strong Q2 revenue, raising 2026 outlook.

Ondas is expanding its market and technology through acquiring Aran Defense Ltd., enhancing its autonomous and defense systems. The company reported record Q2 revenue of $83.8 million, up 67% from the previous quarter and over 13 times year-over-year...

Company Fundamentals
Bullish
4 hours ago
Guidewire Software poised for strong growth with AI-driven cloud transition in P&C insurance sector

Guidewire Software poised for strong growth with AI-driven cloud transition in P&C insurance sector

Guidewire Software (GWRE) is positioned to become a leading AI-enhanced software provider for property and casualty insurance companies, showing 27% year-over-year revenue growth and expanding margins. The company is successfully transitioning custom...

Market News
Bullish
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App